**Name of journal: World Journal of Clinical Cases**

**ESPS Manuscript NO: 12799**

**Columns: MINIREVIEWS**

**Vasopressors in obstetric anesthesia: A current perspective**

Nag DS *et al*. Vasopressors in obstetric anesthesia

Deb Sanjay Nag, Devi Prasad Samaddar, Abhishek Chatterjee, Himanshu Kumar, Ankur Dembla

**Deb Sanjay Nag, Devi Prasad Samaddar, Abhishek Chatterjee, Himanshu Kumar, Ankur Dembla,** Department of Anaesthesiology and Critical Care, Tata Main Hospital, Jamshedpur 831011, India

**Author contributions:** Nag DS and Samaddar DP conceived the concept and the structure of the review; Nag DS, Samaddar DP, Chatterjee A, Kumar H and Dembla A searched the literature and wrote the review; Nag DS and Samaddar DP edited its final manuscript.

**Correspondence to: Dr. Deb Sanjay Nag,** Department of Anaesthesiology and Critical Care, Tata Main Hospital, Jamshedpur 831011, India. debsanjay@gmail.com

**Telephone:** +91-943-1166582  **Fax:** +91-657-2424031

**Received:** July 26, 2014 **Revised:** August 25, 2014

**Accepted:** October 23, 2014

**Published online:**

**Abstract**

Vasopressors are routinely used to counteract hypotension after neuraxial anesthesia in Obstetrics. The understanding of the mechanism of hypotension and the choice of vasopressor has evolved over the years to a point where phenylephrine has become the preferred vasopressor. Due to the absence of definitive evidence showing absolute clinical benefit of one over the other, especially in emergency and high-risk Cesarean sections, our choice of phenylephrine over the other vasopressors like mephentermine, metaraminol, and ephedrine is guided by indirect evidence on fetal acid-base status. This review article evaluates the present day evidence on the various vasopressors used in obstetric anesthesia today.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Vasopressor agents; Obstetrics; Cesarean section; Hypotension; Spinal anesthesia

**Core tip:** Phenylephrine has emerged as the vasopressor of choice in Obstetrics. However, the present recommendations are essentially based on studies conducted in elective Cesarean sections. Further studies are needed in emergency and high risk Cesarean sections in order to clarify whether there is a benefit of phenylephrine over other vasopressors.

Nag DS, Samaddar DP, Chatterjee A, Kumar H, Dembla A. Vasopressors in obstetric anesthesia: a current perspective. *World J Clin Cases* 2014, In press

**INTRODUCTION**

Neuraxial anesthesia remains the preferred choice for Cesarean deliveries across the world. Hypotension is the physiologic consequence of spinal anesthesia and can have a potentially deleterious maternal and fetal impact. Vasopressors, which lead to an increase in systemic vascular resistance and rise in mean arterial pressures[1], have been traditionally used for the prevention and management of hypotension after neuraxial anesthesia. However, the understanding of hypotension after neuraxial anesthesia in obstetrics, and the use of vasopressors to counteract it, continues to evolve over the years. This review article briefly explores the present understanding of the mechanism causing hypotension before discussing the current use of the various vasopressors in obstetric anesthesia today. The authors discuss the various vasopressors used in obstetric anesthesia and put the recent evidence into perspective to guide our clinical practice today.

**HYPOTENSION AFTER NEURAXIAL ANESTHESIA**

The sympathectomy resulting from the neuraxial blockade is exaggerated by the physiological changes of pregnancy and puerperium, leading to hypotension in as much as 55-90% of the mothers receiving spinal anesthesia for Cesarean section[2]. Holmes *et al*[3] and Lees *et al*[4] indicated that the compression of the vena cava by gravid uterus impeded the venous return and caused hypotension. Marx[5] postulated that the subarachnoid block resulted in venous pooling of blood in the lower legs, leading to decreased venous return and reduced cardiac output. Although our present interpretation of the mechanism causing hypotension are still based on these principles, prophylactic therapeutic interventions based upon this understanding do not definitively prevent hypotension after neuraxial anaesthesia in Cesarean sections[6].

Based on studies on pre-eclamptic women, Sharwood-Smith *et al* [6] challenged the understanding that reduced central venous pressure led to decreased cardiac output and arterial pressures. They suggested that "venous capacitance" rather than venous pressure maybe the determinant in causing hypotension after spinal anesthesia in obstetrics. The "endothelium-dependent alteration of vascular smooth muscle function" and increased presence of "vasodilator prostaglandins and nitric oxide" during pregnancy have a vasodilatory effect which is counteracted by the intrinsic sympathetic vascular tone[6]. This intrinsic vascular tone is adversely impacted after spinal anesthesia, leading to exaggerated fall in blood pressure. Studies now show that cardiac output remains nearly unchanged even after sympathetic blockade[7], challenging the concept that in parturients, spinal anesthesia results in decrease in cardiac output[8]. Despite the varied understanding of hypotension following neuraxial anesthesia in pregnancy, vasopressors remain the cornerstone in restoring the arterial pressure and mitigating the possible adverse maternal and fetal impact.

**VASOPRESSORS USED IN OBSTETRICS**

Vasopressors which have been used in obstetrics primarily include the directly acting selective α1 receptors agonists, phenylephrine and methoxamine, and both directly and indirectly acting mephentermine, metaraminol and ephedrine.

**METHOXAMINE**

Methoxamine is an α1 receptor agonist which causes intense vasoconstriction following parenteral administration, raising arterial blood pressure and may result in reflex vagal inhibition of the heart rate[9]. It is devoid of any inotropic or chronotropic effect[9] and has been used to counteract the hypotension caused by spinal anesthesia[10]. Tachyphylaxis has seldom been observed with methoxamine[11]. While the peak vasopressor effect after a single intravenous dose of 2-4 mg has been observed after 0.5-2 min, its duration of action has been reported to be 10-15 min[12]. Intramuscular administration of a 10-40 mg dose has its peak onset of action at 15-20 min and its action lasts for about 1.5 h[12]. Its use in clinical obstetrics has fallen out of favor decades ago owing to concerns regarding decreased uterine blood flow and adverse impact on fetal acid-base status in animal studies[12,13].

**Mephentermine**

It has a mixed α & β receptor agonist action with both direct and indirect effect due to release of norepinephrine and epinephrine[14]. Its impact on the heart rate is dependent on the vagal tone. Its use in hypotension after a neuraxial blockade in obstetrics is due to its ability to increase the blood pressures by augmenting the cardiac output[14]. Tachyphylaxis to the pressor action of mephentermine develops rapidly[15]. While there is immediate onset of action peaking at 5 min and lasting 15-30 min after an intravenous dose, an intramuscular dose starts acting after 5-15 min and has a variable duration of action from 1-4 h. It is commonly used as a 3-5 mg intravenous bolus or intravenous infusion of 2-5 mg/min[16], or 25-50 mg intramuscularly[17]. There is scarce literature evidence on the fetal metabolic effect and placental transfer of mephentermine[18]. However, a few studies have shown that mephentermine is as effective as phenylephrine in preventing maternal hypotension after spinal anesthesia and has similar effect on neonatal outcome[19]. It is being widely used in developing countries like India as it is much more economical[19] than phenylephrine. Moreover, unlike phenylephrine which needs multiple dilutions from the single use 10mg/mL (1 mL) ampoules, mephentermine offers ease of use as it does not necessitates multiple dilutions.

**METARAMINOL**

Although it has both mixed α & β receptor agonist action, its primary clinical use is to counteract the hypotension after spinal anesthesia in obstetrics. It has significant direct effect on vascular α adrenergic receptors along with its indirect action due to the release of norepinephrine[20,21]. Tachyphylaxis develops due to the displacement of norepinephrine from the sympathetic nerve endings by metaraminol and its action as a false neurotransmitter having inhibited vasopressor effect[17]. While an intravenous bolus dose of 0.5-5 mg has its onset of action in 1-2 min, peak action is at 10 min and duration of action is 20-60 min. An intramuscular dose of 2-10 mg has its onset by 10 min and duration of action of 1-1.5 h[22].

**Phenylephrine**

At clinically relevant doses, it is a selective α1 receptor agonist and β agonist action is only seen at much higher doses[20]. It is frequently used in obstetric anesthesia to counteract the hypotension after spinal anesthesia due to marked arterial vasoconstriction caused by its α1 agonist action. Potential negative chronotropic effect is due to reflex bradycardia and decreased cardiac output might not adversely influence the fetus in elective cases[23], but during emergency Cesarean sections with presence of fetal acidosis, any fall in cardiac output may further jeopardize the compromised fetus[23]. However, definitive understanding on the effect of phenylephrine in emergency situations awaits further research[21]. Tachyphylaxis with phenylephrine is possibly caused by the down-regulation of α adrenergic receptors. Its potential to be reversed by hydrocortisone has not been evaluated in an obstetric setting[24].

An intravenous dose of phenylephrine has immediate onset and duration of action of 5-10 min[17]. The optimum regimen for administration of phenylephrine has not yet been defined[25]. Prophylactic administration is associated with a higher incidence of hypertension and bradycardia[26] and treatment after onset of hypotension is associated with higher "incidence and severity of maternal predelivery hypotension"[26]. Despite some studies suggesting that to prevent spinal anesthesia induced hypotension, as an intravenous intermittent bolus dose (ED95) of phenylephrine should be at least 122-147 micrograms[27,28], 40-100 micrograms bolus dose remains the common clinical practice[25].

Prophylactic infusions have been advocated in the range of 25-100 micrograms/min in various studies, but claims have been made that a fixed dose of 50 micrograms/min minimizes the risk of higher incidence of hypotension at lower doses and reactive hypertension, bradycardia and decreased cardiac output at higher doses[23,25,26].

However, prophylactic fixed dose concept has been challenged[26], necessitating further studies to find the advantages of phenylephrine infusion.

It was even suggested in 2010 that "prophylactic fixed rate infusions may have limited application in clinical practice" and further studies into variable rate of phenylephrine infusion is needed[26]. A recent study by Siddik-Sayyid *et al*[29] has failed to demonstrate any difference in neonatal outcome with a variable rate regimen adjusted in response to changes in arterial blood pressure, as compared to prophylactic fixed rate infusion regimen. However, with respect to limiting maternal symptoms, the variable rate regimen was more effective than relying on rescue phenylephrine[29].

Despite these studies, obstetric anesthesiologists are unable to arrive at a consensus opinion on the ideal regimen for administration of phenylephrine beacuse other studies have demonstrated that with intermittent boluses, the total dose requirement is smaller, blood pressure was better maintained in the 1st 6 min after induction, and indeed, good blood pressure control is achievable by intermittent boluses[30], which is not only simple, but also does not need the setting up of a syringe pump[31].

Although not much literature is available on the efficacy of intramuscular phenylephrine, Ayorinde *et al*[32] reported that 4 mg of intramuscular pre-emptive phenylephrine decreased the severity of hypotension and the need for rescue vasopressors in spinal anesthesia induced hypotension.

**Ephedrine**

It has both direct α and β agonist action, but indirect action is more prominent due to the "release of norepinephrine from sympathetic neurons"[20]. It increases the blood pressure by β1 receptor stimulation with increased heart rate and cardiac contractility, whereas the α agonist action causes peripheral vasoconstriction[21,33]. Prophylactic doses of 30 mg intravenous ephedrine had been suggested by Ngan Kee *et al*[34] to achieve significant reduction in the incidence of hypotension, but it was associated with the risk of reactive hypertension in as much as 45% of the patients. Subsequent studies by Kol *et al*[35] also failed to demonstrate beneficial effect of prophylactic intravenous ephedrine at 0.5 mg/kg. Even for a reduction in the need for rescue boluses of ephedrine, at least 12 mg intravenous prophylactic dose of ephedrine is needed after spinal anesthesia for Cesarean sections[36]. Ephedrine’s limited ability to prevent hypotension induced by neuraxial anesthesia is probably related to its slower onset of action[34]. As a rescue vasopressor, 5-15 mg intravenous boluses are most commonly advocated for the treatment of hypotension following neuraxial anesthesia. Its clinical effect is primarily due to its indirect action of releasing norepinephrine from postganglionic nerve endings. The drug not only has delayed onset of action, it also has a longer duration of action of about 60 min. Depletion of presynaptic norepinephrine stores also lead to tachyphylaxis[35]. Due to its delayed onset of action, it should only be repeated after 5-10 min as it was observed that larger doses of ephedrine were required in the first 10 min and often caused overshoot of the desired target systolic pressures after 10 min[37].. Intravenous boluses are therefore preferred to continuous intravenous infusions as the drug exhibits delayed onset of action and tachyphylaxis.

**The Choice of Vasopressor: The recent evidence**

The ideal vasopressor would be one which is reliable and easy to use, has rapid onset, short duration of action, easily titrable, can potentially be used prophylactically and lack any adverse maternal and fetal impact. A Comparative analysis of the commonly used vasopressors in obstetric anesthesia is illustrated in Table 1.

In 2002, Lee *et al*[38] challenged the "traditional idea that ephedrine is the preferred choice". for use as a vasopressor to combat hypotension after spinal anesthesia for Cesarean sections. In a quantitative systemic review they concluded that for elective Cesarean sections, phenylephrine was associated with better fetal acid-base status, although no clinical outcome difference based on the Apgar scores could be established[38].

In patients treated with ephedrine, the cause of decreased pH, base excess and oxygen content in umbilical cord arterial blood is controversial. While earlier studies indicated towards differential action of various vasopressors on uteroplacental circulation[39], studies by Ngan Kee *et al*[40] showed that depressed fetal acid base status was possibly due to ephedrine crossing the placenta and causing depression of fetal pH by its "metabolic effects secondary to stimulation of fetal β-adrenergic receptors". A recent study by Landau *et al* [41] has given a new direction to this debate. They showed that the neonatal homozygosity for Arg16 of *ADRB2* protected from neonatal acidemia in mothers treated with ephedrine[41]. The presence of this genotype in greater that 30% of the Chinese cohort and the fact that their genotype differs considerably from their North Americans indicate that clinicians should be wary of extrapolating studies of one ethnic population group on another[41].

 Despite evidence in favor of phenylephrine as a superior choice, there remains widespread variation in the "choice, dosing, and method of administration of vasopressors"[25]. The United Kingdom National Institute for Health and Care Excellence Guidelines state that ephedrine and phenylephrine are equally efficacious as vasopressors in obstetric anesthesia[42]. The American Society of Anesthesiologists Task Force on Obstetric Anesthesia states that while ephedrine and phenylephrine are both acceptable, "phenylephrine may be preferable because of improved fetal acid-base status in uncomplicated pregnancies"[43]. There is much more clarity in the Canadian guidelines which state that there is "general agreement among experts to recommend the use of phenylephrine" as the first line therapy[8]. Belgian guidelines also recommend phenylephrine as the preferred vasopressor in absence of maternal bradycardia (Grade 1, A)[44].

 While there is abundant literature evidence claiming superiority of phenylephrine over ephedrine in healthy parturients undergoing elective Cesarean section based on fetal acid-base status, there is dearth of evidence showing benefit in clinical outcome. Meta-analysis of 142 studies comparing phenylephrine and ephedrine failed to show the superiority of one over the other while comparing the Apgar scores[45]. However recent systematic review and meta-analysis do show that fetal acidosis defined as pH < 7.20 was associated with four- and two-fold increase in mortality and morbidity, respectively[46].

Due to a dearth of studies on the vasopressor of choice during non-elective Cesarean sections[47], it is suggested that further research is needed in high-risk pregnancies, intra uterine growth retardation, placental insufficiency, pre-eclampsia[25] and in emergency Caesareans due to fetal distress.

In one study in 2008 by Ngan Kee *et al*[48] in non-elective Cesarean sections, there was "no differences in fetal acid-base status or clinical neonatal outcome" between 100 µg phenylephrine and 10mg ephedrine boluses to manage spinal anesthesia induced hypotension. Similarly, a retrospective study by Cooper *et al*[49] on the choice of vasopressor between phenylephrine and ephedrine in high-risk Cesarean sections, there was no statistically significant difference in the umbilical artery pH between the two groups.

There is also scarce literature available on the other vasopressors[50]. Kansal A *et al*[16] concluded that mephentermine can be used as safely as ephedrine in the management of spinal anesthesia-induced hypotension in Cesarean sections. Similarly, Mohta *et al*19] concluded that phenylephrine and mephentermine are equally effective in preventing hypotension after a spinal anesthesia for Cesarean section[. Both the studies compared the Apgar scores and the neonatal acid-base status while evaluating the vasopressors[16,19]. In 2014, studies by Aragao *et al*[50] compared an infusion of metaraminol with phenylephrine and ephedrine and did not find any difference in the incidence of maternal hypotension or neonatal Apgar scores. Comparison of phenylephrine, metaraminol and ephedrine showed that Ephedrine treated mothers had lower pH and base excess in their newborns[50]. However those treated with metaraminol needed fewer rescue boluses as compared to ephedrine, but not phenylephrine[50].

Combination of phenylephrine and ephedrine infusion has also demonstrated deterioration in fetal acid-base status and maternal hemodynamic control with the proportionate increase in the dose of ephedrine[51-53]..

**Conclusion**

Current literature supports the use of phenylephrine as the vasopressors of choice while considering the influence on feto-maternal physiology[25,47]. However, this concept is mostly based on studies conducted in elective Cesarean sections. Therefore, this same principle cannot be extrapolated in emergency Cesarean sections and high-risk pregnancies.

Due to its potential for possible adverse impact on placental perfusion[25] when it causes bradycardia and decreased cardiac output, further studies on phenylephrine are needed, especially in presence of pre-existing fetal compromise.

Certain clinical protocols support the use of phenylephrine in the presence of maternal tachycardia (heart rate > 110/min) and ephedrine at lower heart rates (< 80/min)[54]. A suggested clinical protocol for intravenous use of vasopressor for hypotension after neuraxial anaesthesia in obstetrics is given in Figure 1.

Today, in obstetric anesthesia, both phenylephrine and ephedrine continue to be used in the “absence of relevant evidence, rather than any evidence of the absence of an effect”[55]. The same appears to be true for mephentermine and metaraminol also. Larger trials, especially in non-elective Cesarean sections, would be needed to give further direction to the obstetric anesthesiologists in choosing their preferred vasopressor.

**REFERENCES**

1 **Bangash MN**, Kong ML, Pearse RM. Use of inotropes and vasopressor agents in critically ill patients. *Br J Pharmacol* 2012; **165**: 2015-2033 [PMID: 21740415 DOI: 10.1111/j.1476-5381.2011.01588.x]

2 **Mercier FJ**, Bonnet MP, De la Dorie A, Moufouki M, Banu F, Hanaf A, Edouard D, Roger-Christoph S. [Spinal anaesthesia for caesarean section: fluid loading, vasopressors and hypotension]. *Ann Fr Anesth Reanim* 2007; **26**: 688-693 [PMID: 17590565 DOI: 10.1016/j.annfar.2007.05.003]

3 **Holmes F**. Spinal analgesia and caesarean section; maternal mortality. *J Obstet Gynaecol Br Emp* 1957; **64**: 229-232 [PMID: 13416987 DOI: 10.1111/j.1471-0528.1957.tb02626.x]

4 **Lees MM**, Scott DB, Kerr MG, Taylor SH. The circulatory effects of recumbent postural change in late pregnancy. *Clin Sci* 1967; **32**: 453-465 [PMID: 6067526]

5 **Marx GF**. Supine hypotension syndrome during cesarean section. *JAMA* 1969; **207**: 1903-1905 [PMID: 5818306 DOI: 10.1001/jama.1969.03150230117018]

6 **Sharwood-Smith G**, Drummond GB. Hypotension in obstetric spinal anaesthesia: a lesson from pre-eclampsia. *Br J Anaesth* 2009; **102**: 291-294 [PMID: 19218369 DOI: 10.1093/bja/aep003]

7 **Tamilselvan P**, Fernando R, Bray J, Sodhi M, Columb M. The effects of crystalloid and colloid preload on cardiac output in the parturient undergoing planned cesarean delivery under spinal anesthesia: a randomized trial. *Anesth Analg* 2009; **109**: 1916-1921 [PMID: 19923521 DOI: 10.1213/ANE.0b013e3181bbfdf6]

8 **Loubert C**. Fluid and vasopressor management for Cesarean delivery under spinal anesthesia: continuing professional development. *Can J Anaesth* 2012; **59**: 604-619 [PMID: 22528166 DOI: 10.1007/s12630-012-9705-9]

9 **Imai S**, Shigei T, Hashimoto K. Cardiac actions of methoxamine with special reference to its antagonistic action to epinephrine. *Circ Res* 1961; **9**: 552-560 [PMID: 13717556]

10 **Brienza A**, De Leonardis A. [The choice of the pressor drug in hypotension caused by peridural anesthesia. Observations with methoxamine, metaraminol and mephentermine]. *Acta Anaesthesiol* 1967; **18**: Suppl 2: 11-2: 27 [PMID: 5632249]

11 **Brewster RW,** Osgood PF, Isaacs JP, Goldberg LI, Chock RTW. Hemodynamic effects of a pressor amine (methoxamine) with a predominant vasoconstrictor activity. *Circ Res* 1960; **8:** 980–986 [DOI: 10.1161/01.RES.8.5.980]

12 **RxMed.** (Internet). VASOXYL®. Glaxo Wellcome. Methoxamine HCl. Vasopressor. [accessed 2014 Jul 10]. Available from: http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-%20Monographs/CPS-%20(General%20Monographs-%20V)/VASOXYL.html

13 **Ralston DH**, Shnider SM, DeLorimier AA. Effects of equipotent ephedrine, metaraminol, mephentermine, and methoxamine on uterine blood flow in the pregnant ewe. *Anesthesiology* 1974; **40**: 354-370 [PMID: 4819091 DOI: 10.1097/00000542-197404000-00009]

14 **Hodge RL**, Dornhorst AC. The clinical pharmacology of vasoconstrictors. *Clin Pharmacol Ther* 1966; **7**: 639-647 [PMID: 5334234]

15 **Fawaz G**, Simaan J. The Tachyphylaxis Caused By Mephentermin And Tyramine. *Br J Pharmacol Chemother* 1965; **24**: 526-531 [PMID: 14320866 DOI: 10.1111/j.1476-5381.1965.tb01742.x]

16 **Kansal A**, Mohta M, Sethi AK, Tyagi A, Kumar P. Randomised trial of intravenous infusion of ephedrine or mephentermine for management of hypotension during spinal anaesthesia for Caesarean section. *Anaesthesia* 2005; **60**: 28-34 [PMID: 15601269 DOI: 10.1111/j.1365-2044.2004.03994.x]

17 **Glick DB.** The autonomic nervous system. In: Miller RD, Eriksson LI, Fleisher LA, et al, eds. Miller's Anesthesia. 7th ed. Philadelphia: Elsevier; 2011:261-304

18 **Mitra JK**, Roy J, Bhattacharyya P, Yunus M, Lyngdoh NM. Changing trends in the management of hypotension following spinal anesthesia in cesarean section. *J Postgrad Med* 2013; **59**: 121-126 [PMID: 23793313 DOI: 10.4103/0022-3859.113840]

19 **Mohta M**, Janani SS, Sethi AK, Agarwal D, Tyagi A. Comparison of phenylephrine hydrochloride and mephentermine sulphate for prevention of post spinal hypotension. *Anaesthesia* 2010; **65**: 1200-1205 [PMID: 21182601 DOI: 10.1111/j.1365-2044.2010.06559.x]

20 **Westfall TC,** Westfall DP. Adrenergic agonists and antagonists. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 11 th ed. New York: McGraw Hill, 2006: 237-295

21 **Reidy J**, Douglas J. Vasopressors in obstetrics. *Anesthesiol Clin* 2008; **26**: 75-88, vi-vii [PMID: 18319181 DOI: 10.1016/j.anclin.2007.11.005]

22 **Smith S,** Scarth E, Sasada M. Metaraminol. In: Drugs in Anaesthesia and Intensive Care. 4th ed. Oxford: Oxford University Press, 2011: 214-215

23 **Stewart A**, Fernando R, McDonald S, Hignett R, Jones T, Columb M. The dose-dependent effects of phenylephrine for elective cesarean delivery under spinal anesthesia. *Anesth Analg* 2010; **111**: 1230-1237 [PMID: 20841418 DOI: 10.1213/ANE.0b013e3181f2eae1]

24 **Alhashemi JA**. Reduction of vasopressor requirement by hydrocortisone administration in a patient with cerebral vasospasm. *Br J Anaesth* 2001; **86**: 138-141 [PMID: 11575393 DOI: 10.1093/bja/86.1.138]

25 **Habib AS**. A review of the impact of phenylephrine administration on maternal hemodynamics and maternal and neonatal outcomes in women undergoing cesarean delivery under spinal anesthesia. *Anesth Analg* 2012; **114**: 377-390 [PMID: 22104076 DOI: 10.1213/ANE.0b013e3182373a3e]

26 **Allen TK**, George RB, White WD, Muir HA, Habib AS. A double-blind, placebo-controlled trial of four fixed rate infusion regimens of phenylephrine for hemodynamic support during spinal anesthesia for cesarean delivery. *Anesth Analg* 2010; **111**: 1221-1229 [PMID: 20495139 DOI: 10.1213/ANE.0b013e3181e1db21]

27 **Tanaka M**, Balki M, Parkes RK, Carvalho JC. ED95 of phenylephrine to prevent spinal-induced hypotension and/or nausea at elective cesarean delivery. *Int J Obstet Anesth* 2009; **18**: 125-130 [PMID: 19162468 DOI: 10.1016/j.ijoa.2008.09.008]

28 **George RB**, McKeen D, Columb MO, Habib AS. Up-down determination of the 90% effective dose of phenylephrine for the treatment of spinal anesthesia-induced hypotension in parturients undergoing cesarean delivery. *Anesth Analg* 2010; **110**: 154-158 [PMID: 19910625 DOI: 10.1213/ANE.0b013e3181c30b72.]

29 **Siddik-Sayyid SM**, Taha SK, Kanazi GE, Aouad MT. A randomized controlled trial of variable rate phenylephrine infusion with rescue phenylephrine boluses versus rescue boluses alone on physician interventions during spinal anesthesia for elective cesarean delivery. *Anesth Analg* 2014; **118**: 611-618 [PMID: 24299932 DOI: 10.1213/01.ane.0000437731.60260.ce]

30 **Doherty A**, Ohashi Y, Downey K, Carvalho JC. Phenylephrine infusion versus bolus regimens during cesarean delivery under spinal anesthesia: a double-blind randomized clinical trial to assess hemodynamic changes. *Anesth Analg* 2012; **115**: 1343-1350 [PMID: 23011562 DOI: 10.1213/ANE.0b013e31826ac3db]

31 **Ngan Kee WD**. Phenylephrine infusions for maintaining blood pressure during spinal anesthesia for cesarean delivery: finding the shoe that fits. *Anesth Analg* 2014; **118**: 496-498 [PMID: 24557093 DOI: [PMID: ]

32 **Ayorinde BT**, Buczkowski P, Brown J, Shah J, Buggy DJ. Evaluation of pre-emptive intramuscular phenylephrine and ephedrine for reduction of spinal anaesthesia-induced hypotension during Caesarean section. *Br J Anaesth* 2001; **86**: 372-376 [PMID: 11573527 DOI: 10.1093/bja/86.3.372]

33 **Kee VR**. Hemodynamic pharmacology of intravenous vasopressors. *Crit Care Nurse* 2003; **23**: 79-82 [PMID: 12961786]

34 **Ngan Kee WD**, Khaw KS, Lee BB, Lau TK, Gin T. A dose-response study of prophylactic intravenous ephedrine for the prevention of hypotension during spinal anesthesia for cesarean delivery. *Anesth Analg* 2000; **90**: 1390-1395 [PMID: 10825326 DOI: 10.1097/00000539-200006000-00024]

35 **Kol IO**, Kaygusuz K, Gursoy S, Cetin A, Kahramanoglu Z, Ozkan F, Mimaroglu C. The effects of intravenous ephedrine during spinal anesthesia for cesarean delivery: a randomized controlled trial. *J Korean Med Sci* 2009; **24**: 883-888 [PMID: 19794988 DOI: 10.3346/jkms.2009.24.5.883]

36 **Loughrey JP**, Walsh F, Gardiner J. Prophylactic intravenous bolus ephedrine for elective Caesarean section under spinal anaesthesia. *Eur J Anaesthesiol* 2002; **19**: 63-68 [PMID: 11915786 DOI: 10.1017/S0265021502000108]

37 **Ngan Kee WD**, Lau TK, Khaw KS, Lee BB. Comparison of metaraminol and ephedrine infusions for maintaining arterial pressure during spinal anesthesia for elective cesarean section. *Anesthesiology* 2001; **95**: 307-313 [PMID: 11506099 DOI: 10.1097/00000542-200108000-00009]

38 **Lee A**, Ngan Kee WD, Gin T. A quantitative, systematic review of randomized controlled trials of ephedrine versus phenylephrine for the management of hypotension during spinal anesthesia for cesarean delivery. *Anesth Analg* 2002; **94**: 920-96, table of contents [PMID: 11916798 DOI: 10.1097/00000539-200204000-00028]

39 **Ngan Kee WD**. Prevention of maternal hypotension after regional anaesthesia for caesarean section. *Curr Opin Anaesthesiol* 2010; **23**: 304-309 [PMID: 20173633 DOI: 10.1097/ACO.0b013e328337ffc6]

40 **Ngan Kee WD**, Khaw KS, Tan PE, Ng FF, Karmakar MK. Placental transfer and fetal metabolic effects of phenylephrine and ephedrine during spinal anesthesia for cesarean delivery. *Anesthesiology* 2009; **111**: 506-512 [PMID: 19672175 DOI: 10.1097/ALN.0b013e3181b160a3]

41 **Landau R**, Liu SK, Blouin JL, Smiley RM, Ngan Kee WD. The effect of maternal and fetal β2-adrenoceptor and nitric oxide synthase genotype on vasopressor requirement and fetal acid-base status during spinal anesthesia for cesarean delivery. *Anesth Analg* 2011; **112**: 1432-1437 [PMID: 21613201 DOI: 10.1213/ANE.0b013e3182179424]

42 **Soltanifar S**, Russell R. The National Institute for Health and Clinical Excellence (NICE) guidelines for caesarean section, 2011 update: implications for the anaesthetist. *Int J Obstet Anesth* 2012; **21**: 264-272 [PMID: 22541846 DOI: 10.1016/j.ijoa.2012.03.004]

43 **American Society of Anesthesiologists Task Force on Obstetric Anesthesia.** Practice guidelines for obstetric anesthesia: an updated report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia. *Anesthesiology* 2007; **106**: 843-863 [PMID: 17413923 DOI: 10.1097/01.anes.0000264744.63275.10]

44 **Van De Velde M**. Belgian guidelines for safe regional anesthesia and obstetric anesthesia and analgesia. *Acta Anaesthesiol Belg* 2013; **64**: 95-96 [PMID: 24279197]

45 **Biddle C**. To press or not to press, and if so, with what? A single question-focused meta-analysis of vasopressor choice during regional anesthesia in obstetrics. *AANA J* 2013; **81**: 261-264 [PMID: 24133847]

46 **Malin GL**, Morris RK, Khan KS. Strength of association between umbilical cord pH and perinatal and long term outcomes: systematic review and meta-analysis. *BMJ* 2010; **340**: c1471 [PMID: 20466789 DOI: 10.1136/bmj.c1471]

47 **Dyer RA**, Biccard BM. Ephedrine for spinal hypotension during elective caesarean section: the final nail in the coffin? *Acta Anaesthesiol Scand* 2012; **56**: 807-809 [PMID: 22780437 DOI: 10.1111/j.1399-6576.2012.02719.x]

48 **Ngan Kee WD**, Khaw KS, Lau TK, Ng FF, Chui K, Ng KL. Randomised double-blinded comparison of phenylephrine vs ephedrine for maintaining blood pressure during spinal anaesthesia for non-elective Caesarean section\*. *Anaesthesia* 2008; **63**: 1319-1326 [PMID: 19032300 DOI: 10.1111/j.1365-2044.2008.05635.x]

49 **Cooper DW**, Sharma S, Orakkan P, Gurung S. Retrospective study of association between choice of vasopressor given during spinal anaesthesia for high-risk caesarean delivery and fetal pH. *Int J Obstet Anesth* 2010; **19**: 44-49 [PMID: 19945278 DOI: 1010.1016/j.ijoa.2009.06.002]

50 **de Aragãoa FF,** de Aragãob PW,  [de Souza Martins](http://www.sciencedirect.com/science/article/pii/S0104001414000682) CA, [Filho](http://www.sciencedirect.com/science/article/pii/S0104001414000682) NS,  [de Souza Barcelos Barroqueiro](http://www.sciencedirect.com/science/article/pii/S0104001414000682) E. Comparison of metaraminol, phenylephrine and ephedrine in prophylaxis and treatment of hypotension in cesarean section under spinal anesthesia. *Rev Bras Anestesiol* 2014; **64:** 299-306 [DOI: 10.1016/j.bjane.2013.07.014]

51 **Ngan Kee WD**, Lee A, Khaw KS, Ng FF, Karmakar MK, Gin T. A randomized double-blinded comparison of phenylephrine and ephedrine infusion combinations to maintain blood pressure during spinal anesthesia for cesarean delivery: the effects on fetal acid-base status and hemodynamic control. *Anesth Analg* 2008; **107**: 1295-1302 [PMID: 18806043 DOI: 10.1213/ane.0b013e31818065bc]

52 **Mercier FJ**, Riley ET, Frederickson WL, Roger-Christoph S, Benhamou D, Cohen SE. Phenylephrine added to prophylactic ephedrine infusion during spinal anesthesia for elective cesarean section. *Anesthesiology* 2001; **95**: 668-674 [PMID: 11575540 DOI: 10.1097/00000542-200109000-00020]

53 **Cooper DW**, Carpenter M, Mowbray P, Desira WR, Ryall DM, Kokri MS. Fetal and maternal effects of phenylephrine and ephedrine during spinal anesthesia for cesarean delivery. *Anesthesiology* 2002; **97**: 1582-1590 [PMID: 12459688 DOI: 10.1097/00000542-200212000-00034]

54 **Tulane Department of Anesthesiology.** Obstetric Anesthesia Guidelines. [accessed 2014 July 19]. Available from: http: //tulaneanesthesiology.com/web/data/documents/Jul2009 TulOBAnesGuidelines.pdf

55 **Heesen M**, Kölhr S, Rossaint R, Straube S. Prophylactic phenylephrine for caesarean section under spinal anaesthesia: systematic review and meta-analysis. *Anaesthesia* 2014; **69**: 143-165 [PMID: 24588024 DOI: 10.1111/anae.12445]

**P-Reviewer:** Do SH, McCarthy RJ, Rasmussen S, Shi ZJ, Zafrakas M **S-Editor:** Tian YL

**L-Editor: E-Editor:**

**Figure 1 Suggested clinical protocol for intravenous use of vasopressor for Hypotension after Neuraxial Anaesthesia in Obstetrics.**



**Table 1 Comparative analysis of vasopressors used in obstetric anesthesia**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **No.** | **Drug** | **Mechanism of Action** | **Advantage** | **Disadvantage** |
| 1 | Methoxamine | α1 receptor agonist | No inotropic or chronotropic effect.Tachyphylaxis has seldom been observed. | Reflex bradycardia.Adverse effect on fetal acid-base status. |
| 2 | Mephentermine | α and β receptor agonist.Both direct and indirectly acting | Economical and does not need multiple dilutions as compared to Phenylephrine. | Tachyphylaxis. Little evidence available on placental transfer and its fetal metabolic impact. |
| 3 | Metaraminol | α and β receptor agonist.Both direct and indirectly acting. | No adverse effect on fetal acid-base status as compared to ephedrine. | Tachyphylaxis. |
| 4 | Phenylephrine | Selective α1 receptor agonist at clinical doses. | Immediate onset and short duration of action. Ideal for continuous infusion.No adverse effect on fetal acid-base status as compared to ephedrine. | Tachyphylaxis.Reflex bradycardia and concerns regarding decreased maternal cardiac output. |
| 5 | Ephedrine | α and β receptor agonist.Both direct and indirectly acting. | Economical and does not need multiple dilutions as compared to Phenylephrine. No bradycardia. | Tachyphylaxis.Adverse effect on fetal acid-base status as compared to Phenylephrine. |